THE RON ONCOGENIC ACTIVITY INDUCED BY THE MEN2B-LIKE SUBSTITUTION OVERCOMES THE REQUIREMENT FOR THE MULTIFUNCTIONAL DOCKING SITE by Santoro, Massimo Mattia et al.
SHORT REPORT
The Ron oncogenic activity induced by the MEN2B-like substitution
overcomes the requirement for the multifunctional docking site
Massimo Mattia Santoro1, Lorenza Penengo2, Sara Orecchia2, Michele Cilli3 and
Giovanni Gaudino*,1
1Dibit-HSR, via Olgettina 58, I-20138, Milano, Italy; 2Department of Medical Sciences, University of Piemonte Orientale ‘Amedeo
Avogadro’, Via Solaroli 17, Novara 28100, Italy; 3(IST) Istituto Nazionale per la Ricerca sul Cancro, L.go R. Benzi 10, I-16132
Genova, Italy
Oncogenic activation of the Ron tyrosine kinase (Macro-
phage Stimulating Protein receptor) relies on substitutions
of two highly conserved residues in the catalytic domain
(D1232V and M1254T), which result in ligand-indepen-
dent activation of the receptor, in vivo tumorigenesis and
metastasis. We show here that the Y/F conversion of
the Y1317 residue in the kinase domain impairs tumorigenic
and metastatic properties of Ron activated by the
MEN2B-like mutation (RonM1254T), but not by other two
oncogenic substitutions. Furthermore, RonM1254T lacking
the multifunctional docking site retains transforming and
metastatic activity. These data reveal that the transform-
ing activity of RonM1254T mutant is dependent on Y1317
phosphorylation, suggesting a shift in intramolecular
substrate specificity. Consistently, a shift of RonM1254T
kinase substrate specificity was observed by in vitro
peptide phosphorylation assays and in vivo receptor auto-
phosphorylation. The Y1317 phosphorylation elicits by itself
activation of PI-3K/Akt and MAPK signalling pathways.
Our data indicate that the accomplishment of the full
oncogenic phenotype of RonM1254T requires the phosphor-
ylation both of the canonical C-terminal docking site and
of the unique Y1317 residue in the tyrosine kinase domain.
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Ron is the receptor for MSP (Macrophage Stimulating
Protein; Gaudino et al., 1994; Wang et al., 1994).
Upon ligand stimulation, Ron signalling occurs
through association to multiple eectors, as a con-
sequence of the phosphorylation of a unique multi-
functional docking site (Y1353VQLPATY1360MNL),
conserved in the evolutionary related Met and Sea
receptors (Ponzetto et al., 1994; Iwama et al., 1996;
Wang et al., 1996).
Receptor tyrosine kinases become oncogenic through
a variety of mechanisms – including overexpression,
point mutations, partial deletions and gene rearrange-
ments – resulting in constitutive activation of the
catalytic domain. Examples of activating mutations,
directly aecting the structure of the TK domain are
those found in the tyrosine kinases Kit, Met and Ret,
associated to human mast cell leukaemia and human
mastocytosis (Longley et al., 1996), to HPRC (Human
Papillary Renal Carcinoma; Schmidt et al., 1997) and
to MEN2B (Multiple Endocrine Neoplasia type 2B;
Carlson et al., 1994). These consist of the substitution
of a conserved aspartic acid residue in subdomain VII
of the kinase with a neutral residue (in Kit and Met)
and of a methionine residue in subdomain VIII of the
kinase into threonine (in Met and Ret). Interestingly,
these residues are highly conserved among the receptor
tyrosine kinases, but have dierent identities in the
cytosolic, non-receptor tyrosine kinases. Constitutive
activation of a tyrosine kinase receptor can occur also
by alteration of the sequence of the transmembrane
domain. This is the case of p185neu*, an oncogenic form
of Neu, where a V?E substitution at position 664
induces constitutive dimerization, tyrosine kinase
autophosphorylation and cell transformation (Weiner
et al., 1989; Sternberg and Gullick, 1989).
The Ron receptor acquires oncogenic potential by
means of two single amino acid substitutions (RonD1232V
and RonM1254T), targeted to the above mentioned
conserved residues in the activation loop of the
tyrosine kinase domain (Santoro et al., 1998; Williams
et al., 1999).
In the present investigation we addressed the
molecular mechanisms responsible for cell transforma-
tion by oncogenic Ron, abrogating potentially alter-
native phosphorylation sites in dierent Ron oncogenic
mutants. These were the previously described receptors
carrying D1232V and M1254T substitutions respec-
tively (Santoro et al., 1998) and the RonNeu* chimaera,
where the transmembrane domain is replaced by the
corresponding sequence of oncogenic p185neu*. A
similar strategy has been used to generate a constitutive
active and transforming PDGFb/Neu* receptor (Petti
et al., 1998).
Sequence analysis of the Ron intracellular region
identified, among several potential alternative sub-
strates, the sequence LY1317QVM that: (i) contains a
very conserved tyrosine residue among the members of
the receptor tyrosine kinase family (Hanks and Quinn,
1991), (ii) outlines a putative docking site for SH2-
containing proteins (Songyang et al., 1993), (iii)
features a phosphorylation consensus for tyrosine
kinases of the cytosolic type (Songyang and Cantley,
1995). This tyrosine was converted to phenylalanine in
all mutationally activated Ron receptors (‘single F’
mutation: Y/F1317). Mutants suppressing the multi-
functional docking site (‘double F’ mutation: Y/F1353,
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Y/F1360) were also generated as well as combined ‘triple
F’ (Y/F1317, Y/F1353, Y/F1360) mutants (Figure 1).
Wild-type and mutant cDNAs were tested for focus
forming activity in NIH3T3 fibroblasts. As previously
shown (Santoro et al., 1998), wild-type Ron was totally
ineective on cell transformation, whereas RonD1232V
and RonM1254T were highly transforming. Interestingly,
the RonNeu* chimaera yielded the highest number of
foci (957/10 mg transfected cDNA). The transforming
properties of RonD1232V and RonNeu* were completely
abolished by ‘double F’ and ‘triple F’ mutations.
Surprisingly, the ‘double F’ suppression mutant, when
generated in RonM1254T, preserved the transforming
ability of this receptor, although half-reduced. Con-
versely, the ‘single F’ substitution of residue Y1317 did
not alter the focus forming activity of RonNeu* and
RonD1232V, whereas in the case of RonM1244T the number
of foci was significantly reduced, being 50% less.
Interestingly, ‘triple F’ mutations, suppressing both the
multifunctional docking site and the Y1317 site, totally
abolished transforming ability of RonD1232V and
RonNeu*, while a residual number of foci were induced
by this mutant generated in RonM1254T (Figure 2). These
data demonstrate that the M1254T substitution forces
RonM1254T to become partially independent from the
phosphorylation of the canonical docking site.
We have previously demonstrated that NIH3T3 cells
expressing RonD1232V and RonN1254T mutants mediate
metastasis formation in nude mice (Santoro et al.,
1998). Similar results were obtained for Met (Jeers et
Figure 1 Schematic representation, expression and tyrosine
auto-phosphorylation of the Ron mutants. (a) Schematic
representation of the oncogenic mutations and tyrosine
substitutions in the Ron receptor. In the mutant RonNeu* the
native transmembrane domain was replaced by that of the
oncogenic rat neu (tm-neu*). The Ron mutationally active
RonD1232V and RonM1254T were generated by single point
substitution in activation loop of the conserved residues
D1232V and M1254T, respectively. The Y/F substitution of
the critical tyrosine residues of the canonical multifunctional
docking site (Y1353F and Y1360F) as well as of the putative
alternative phosphorylation site (Y1317F) are indicated in
underlined italic. The cDNA encoding for Ron, RonD1232V
and RonM1254T have been previously described (Gaudino et al.,
1994; Santoro et al., 1998). The chimeric RonNeu* receptor was
generated by replacing the transmembrane (TM) domain of
human Ron with that of rat p185neu*, bearing the oncogenic
Val/Glu664 substitution. PCR mutagenesis was employed to
generate a unique SfiI site, used for deleting the fragment
encoding the TM domain of Ron. Synthetic double-stranded
oligonucleotides (sense 60 bp: 5’-TGTTCCTAATATTAGTG-
GTGGTCGTTGGAATCCTAATCCGGAGGAACAGCTAGT-
TCTTC-3’; antisense 79 bp: 5’-ACCACTAATATTAGGAA-
CAGCAGGACGCCCTCTACAGTTGCAATGATGAATGTC-
ACCGTGCTCTGGACCCCATCTG-3’) were inserted into the
SfiI site, generating the RonNeu* chimaera. All single (F),
double (2F) and triple (3F) tyrosine/phenylalanine (Y/F) point
mutations were introduced by site-directed mutagenesis, using
the pAlterSites in vitro Mutagenesis System (Promega). Muta-
tions were confirmed by direct DNA cycle-sequencing (Amer-
sham). (b) Expression and tyrosine phosphorylation of Ron
mutants in NIH3T3 cells. All constructs were inserted in the
pMT2 eukaryotic expression vector and co-transfected with
pSVneo in NIH3T3 mouse embryo fibroblasts by the DNA-
calcium phosphate procedure. The transfectants were selected in
growth medium supplemented with 0.4 mg/ml of G418-sulphate.
The panel shows Western analysis on anti-Ron immunopreci-
pitates from lysates of pooled NIH3T3 stable cell lines,
expressing the indicated wild-type or mutated receptors, using
anti-Ron antiserum (Gaudino et al., 1994) or anti-phosphotyr-
osine antibody (Upstate Biotechnology Inc.). Immunoprecipita-
tion and Western blotting experiments were performed as
previously described (Santoro et al., 1998)
Figure 2 Oncogenic and metastatic properties of the Ron
mutants. Transforming activity and in vivo experimental metas-
tasis of NIH3T3 cells expressing the mutated Ron constructs. The
focus forming assays were performed on NIH3T3 fibroblasts
(56105 cells) that were co-transfected with 10 mg of each
recombinant plasmid and 0.8 mg of pSV2-neo using the calcium
phosphate precipitation technique (CellPhect, Pharmacia).
Twenty-four hours after DNA transfection the cultures were split
at low cell density into a 100 mm dishes, and incubated in
DMEM medium supplemented with 5% foetal bovine serum. The
cell cultures were maintained at confluence and screened for foci
formation 15 – 21 days later. All experiments were performed in
triplicates and values represent the average (+s.d). Spontaneous
formation of foci was negligible. To verify the transfection
eciency, a fraction of cells were selected in G418-containing
medium. Cells derived from foci were used only to test protein
expression. To avoid clonal variability, in the Ron-mediated
experimental lung colonization, 106 cells from pooled G418-
selected NIH3T3 populations expressing each type of construct,
were injected intravenously into the tail vein of athymic female
nu/nu mice, as previously described (Santoro et al., 1998). The
animals were subsequently observed for lung metastases for next 2
months. nd: not determined
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al., 1998). Thus, we investigated whether the Y?F
conversion of residue 1317 could also aect lung tissue
colonization induced by Ron oncogenic forms. G418-
resistant NIH3T3 cells, expressing equal levels of
mutationally activated Ron, carrying or not the ‘Y/F’
substitutions, were injected intravenously into the tail
vein of athymic nu/nu mice, subsequently examined for
evidence of lung metastases. Six weeks after injection
of cells expressing both RonNeu* and its Y/F1317 mutant,
severe lung metastases were present in all sacrificed
animals. Metastasis formation was equally observed for
RonD1232V and for its Y/F1317 mutant, both after a longer
latency of 8 weeks. Surprisingly, the Y/F1317 substitu-
tion totally abolished the strong metastatic phenotype
induced by RonM1254T, whereas suppression of multi-
functional docking site in RonM1254T maintained the
ability to induce transformation and metastasis (Figure
2). The importance of Y1317 is highlighted by the fact
that all animals injected with cells expressing the
‘double F’ mutant exhibited severe lung metastases,
as in the case of non mutagenized RonM1254T (data not
shown). These results obtained in vivo reveal that the
M1254T mutation completely subverts the canonical
docking site required for Ron-induced lung tissue
colonization.
It has been suggested that the M/T substitutions in
the activation loop of Ret (Songyang et al., 1995;
Santoro et al., 1995), Kit (Piao et al., 1996) and Met
(Bardelli et al., 1998), can induce a subversion of
substrate specificity of the kinase. To investigate
whether M1254T mutation could alter the Ron
substrate fidelity, we performed in vitro phosphoryla-
tion assays on optimal peptide substrates for EGF
receptor (EGFR) and for the Abl and Src cytosolic
kinases, using Ron and RonM1254T recombinant kinases
expressed in insect cells. A marked alteration in
substrate specificity was observed for the RonM1254T
kinase, which phosphorylated eciently the peptides
optimal substrate both for EGFR and for the cytosolic
tyrosine kinase Abl. These results reveal that the
M1254T substitution uniquely confers substrate speci-
ficity of the cytosolic-type to the Ron kinase, in
addition to its original unaltered specificity for
substrates of the receptor-type (Figure 3a). Conversely,
the other two oncogenic mutations did not aect Ron
substrate specificity (data not shown). This might
explain why RonM1254T phosphorylates both the tyrosine
residues of the multifunctional docking site and Y1317
residue, because the latter is embedded in a consensus
sequence typical of cytosolic-type tyrosine kinases
(Songyang and Cantley, 1995). Consistently, the level
of in vivo tyrosine phosphorylation (receptor trans-
autophosphorylation) was markedly reduced only in
cells expressing RonM1254T F, but not RonM1254T 2F
(Figure 1b). This suggests for the Y1317 residue the role
of an alternative optimal tyrosine phosphorylation site
for the kinases bearing the M1254T substitution.
It has been demonstrated that the Ron signalling to
cell interior requires at least activation both of the
PI3-kinase/Akt and of Ras/MAPK pathways (Li et
al., 1995; Wang et al., 1996; Santoro et al., 1996).
This prompted us to investigate how mutationally
activated RonM1254T aects these signalling pathways in
cells expressing RonM1254T and its Y/F mutants. By
using antibodies recognizing the phosphorylated
(activated) form of Akt and MAPK, we found that
phosphorylation of residue Y1317 in the RonM1254T
receptor devoid of a functional canonical docking site
(RonM1254T 2F) led to activation of Akt and MAPK
eectors. On the contrary, the corresponding mutants
of RonNeu* and RonD1232V (RonNeu* 2F and RonD1232V
2F) were totally inactive on these pathways (Figure 3b
and data not shown). Moreover, RonM1254T delivered a
stronger signal that RonNeu* and RonD1232V, possibly
because of the synergy between the two phosphotyr-
osine motifs (Y1317 and YY1353,1360) occurring only in the
receptor bearing the M1254T mutation. This assump-
tion is strengthened by the fact that abrogation of
Y1317 in RonM1254T F) reduces by half the levels of Akt
Figure 3 Peptide substrate selectivity of Ron and RonM1254T
kinases and Ron mutant-induced AKT/PKB and MAPK
activation. (a) Phosphorylation assay on peptide substrates to
determine the catalytic specificity of Ron and RonM1254T kinases.
Ron and RonM1254T intracellular domain were cloned in the
Baculovirus Transfer Vector pBlueBacHis2 (Invitrogen) and
expressed in recombinant form using Sf9 baculovirus cells. The
insect cells were lysed 72 h after infection in lysis buer
containing 1% Triton X-100, 2 mM sodium orthovanadate and
inhibitors of proteases (aprotinin, 1 mg/ml; leupeptin, 500 mg/ml;
phenilmethanelsulphonyl fluoride, 1 mM). The cellular extracts
were immunoprecipitated with Sepharose-protein A (Amersham-
Pharmacia) and with Ron C-terminal antisera, and used to
phosphorylate the optimal peptide substrates for epidermal
growth factor receptor (EGFRs) AEEEEYFELVAKKKK
(100 mM), Src (SRCs) AEEEIYGEFEAKKK (100 mM), Abl
(ABLs) EAIYAAPFAKKK (100 mM) and Ron (RONs) RDIL-
DREYYSVQQHR (100 mM). The reaction was performed in the
kinase buer (25 mM HEPES, pH 7.5, 5 mM MnCl2, 2 mM DTT)
in the presence of [g-32P]ATP for 15 min at 48C (Songyang et al.,
1994). The amount of radioactivity incorporated was determined
using the phosphocellulose assay (Pierce). The error bars indicate
the standard deviation between two independent experiments. (b)
Eect of Y/F substitution on oncogenic Ron-mediated activation
of AKT and MAPK signalling pathways. Total cell lysate (20 mg)
from NIH3T3 cells expressing the indicate mutants were analysed
by SDS–PAGE and Western blotting with anti active-Akt (anti-
phospho S473 Akt, New England Biolabs) or anti active-MAPK
(anti-diphosphorylated MAPK, Sigma) antibodies, respectively.
The cells were serum-starved for 16 h before the lysis
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and MAPK activities, in contrast to what occurs in
the case of the corresponding RonNeu* mutant (RonNeu*
F), that maintain unchanged these activities (Figure
3b).
These results show that the RonM1254T F and
RonM1254T 2F mutants, when independently expressed,
do not abrogate completely the signalling, which is
maintained at appreciable levels. This is explained by a
specific eect of the M1254T mutation, leading residue
Y1317 and multifunctional docking site to vicariate each
other in transducing the signal triggered by RonM1254T
kinase. On the other hand, the M1254T mutation can
enhance signalling because of the specific engagement
of residue Y1317 in addition of the conventional C-
terminal docking site.
The pattern is completely dierent for the other two
mutationally active Ron receptors, RonNeu* and
RonD1232V. Here the abrogation of the multifunctional
docking site totally suppressed Ron signalling and
consequently transformation and metastasis. More-
over, in these oncogenic Ron receptors, the expression
of the Y/F1317 substitution did not aect signalling and
biological activity at all.
Recently, similar results were obtained for the
mutationally activated Met receptor, bearing L1213V
or M1268T substitutions, that overcomes the require-
ment for the phosphorylation of the multifunctional
docking site. This suggests that the activating muta-
tions stabilize an active conformation of the Met
kinase, signalling through mechanisms distinct from
those of wild-type Met (Jeers and Vande Woude,
1999).
In conclusion, our results demonstrate that the Ron
receptor carrying the M1254T mutation requires for
the attainment of its full oncogenic program the
phosphorylation of the unique Y1317 residue as well as
of the canonical C-terminal docking site. This is the
first demonstration by in vivo assays that the MEN2B-
like amino acid substitution influences the biological
properties of a tyrosine kinase receptor, by altering its
substrate specificity.
It will be interesting to investigate whether a similar
behaviour occurs in Ret and Met receptors, that are
targets of the same M/T mutation in MEN2B and
HPRC neoplasia, respectively.
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